FDA Scrutiny Looms Over RSV Antibody Shots for Babies

Doctors express concern regarding potential FDA scrutiny of new antibody shots designed to protect babies from severe RSV infections. While drugmakers maintain the safety of these treatments, which are about 80% effective at preventing intensive care admissions, the regulatory review process has raised questions among medical professionals. This development underscores the ongoing tension between rapid medical innovation and the rigorous safety standards required for pediatric vaccines.